gaboxadol (OV101) - Ovid Therapeutics, Healx
Social regression stems from a latent phase of GABAergic dysfunction and sensory breakdown in a model of synaptopathy. (PubMed, Mol Psychiatry) - Jul 14, 2026 - "Boosting tonic inhibition from birth with chronic treatment with the GABAA receptor agonist gaboxadol fully reversed social deficits, restored the integrity of vocal circuits, and the multimodal integration of sensory inputs. These results show that social regression in the Syn2KO model is a multiphase process characterized by early signs, a latent period of typical development, and a subsequent decline that can be reversed by enhancing tonic inhibition from development onward." 
Journal • Autism Spectrum Disorder • CNS Disorders • Epilepsy • Genetic Disorders • NAPSB
http://www.ncbi.nlm.nih.gov/pubmed/42443391
 
Alessandro Esposito; Andrea Armirotti; Anna Fassio; Arianna Benedetti; Caterina Michetti; Chiara Penzo; Dmytro Shmal; Elisabetta Colombo; Fabio Benfenati; Filippo Galluzzi; Francesca Franchi; Lorenzo Ciano; Martino Caramia; Sebastian Sulis Sato; Sine Mandrup Bertozzi
 
Jul 14, 2026
 
Prev Next